New antibody AHA-1031 shows potential in treating non small cell lung cancer resistant to immunotherapy, offering new hope.
Vous n'êtes pas connecté
An experimental therapy AHA-1031 significantly reduced the size of treatment-resistant lung cancer tumors in animal models by stimulating an immune response from natural killer (NK) cells.
New antibody AHA-1031 shows potential in treating non small cell lung cancer resistant to immunotherapy, offering new hope.
Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment. However, cancer cells have...
New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove to...
A new artificial intelligence model has demonstrated high accuracy in detecting and outlining lung tumors on CT scans, according to a study...
Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the donor's immune cells...
University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of cancer-fighting immune cells...
Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the treatment itself caused any...
When blood cancer cells break through the bone and multiply, tumour cells become dangerously diverse and the immune response in the region changes,...
Red light therapy is increasingly viewed as a promising treatment for wrinkles, acne, psoriasis, scars and sun-damaged skin, and as a supportive...
University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut...